4D today announced the presentation of a trial in progress poster from the Phase II clinical trial of MRx0518 in combination with BAVENCIO at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The study is being conducted in collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Positive Update on MRx0518
- Published:
27 May 2022 -
Author:
Karl Keegan -
Pages:
3
4D today announced the presentation of a trial in progress poster from the Phase II clinical trial of MRx0518 in combination with BAVENCIO at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The study is being conducted in collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc.